Acceptability of human papillomavirus vaccines among women older than 26 years

Vaccine

Volumn 33, Issue 13, 2015, Pages 1556-1561

  Dempsey, Amanda F ^a   Brewer, Sarah E ^a   Pyrzanowski, Jennifer ^a   Sevick, Carter ^a   O'leary, Sean T ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Human papillomavirus; Vaccine

Indexed keywords

WART VIRUS VACCINE;

ADULT; AGED; ANALYSIS; ARTICLE; BINOMIAL DISTRIBUTION; CHI SQUARE TEST; CONDYLOMA ACUMINATUM; CONVENIENCE SAMPLE; FEMALE; GENERAL PRACTITIONER; HEALTH INSURANCE; HUMAN; MACNEMAR ANALYSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SELF REPORT; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS; AGE; ATTITUDE TO HEALTH; COLORADO; ECONOMICS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PATIENT ATTITUDE; QUESTIONNAIRE; STATISTICS AND NUMERICAL DATA;

ADULT; AGE FACTORS; AGED; COLORADO; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT ACCEPTANCE OF HEALTH CARE; SURVEYS AND QUESTIONNAIRES;

EID: 84924979981     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.02.018     Document Type: Article

References (34)

1. The Future II Study Group Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis 2007, 196(10):1438-1446.
2. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004, 364:1757-1765.
3. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Paavonen J., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006, 95:1459-1466.
4. Schwarz T.F., Spaczynski M., Schneider A., Wysocki J., Galaj A., et al. Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years. Hum Vaccin 2011, 7:958-965.
5. Schiller J.T., Castellsague X., Garland S.M. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012, 30(5):F123-F138.
6. Castellsague X., Munoz N., Pitisuttithum P., Ferris D., Monsonego J., et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer 2011, 105:28-37.
7. Public Health Agency of Canada Recommended immunization schedule, adults, not previously immunized 2014.
8. Mazza D., Petrovic K., Grech C., Harris N. HPV vaccination in women aged 27 to 45 years: what do general practitioners think?. BMC Womens Health 2014, 14:91.
9. Vousden K.H., Farrell P.J. Viruses and human cancer. Br Med Bull 1994, 50:560-581.
10. Black L.L., Zimet G.D., Short M.B., Sturm L., Rosenthal S.L. Literature review of human papillomavirus vaccine acceptability among women over 26 years. Vaccine 2009, 27:1668-1673.
11. Dunne E.F., Unger E.R., Sternberg M., McQuillan G., Swan D.C., et al. Prevalence of HPV infection among females in the United States. JAMA 2007, 297:813-819.
12. Dempsey A.F., Davis M.M. Overcoming barriers to adherence to HPV vaccination recommendations. Am J Manag Care 2006, 12:S484-S491.
13. Small S.L., Sampselle C.M., Martyn K.K., Dempsey A.F. Modifiable influences on female HPV vaccine uptake at the clinic encounter level: a literature review. J Am Assoc Nurse Pract 2014, 26(9):519-525.
14. Wong K.Y., Do Y.K. Are there socioeconomic disparities in women having discussions on human papillomavirus vaccine with health care providers?. BMC Womens Health 2012, 12:33.
15. Harris P., Taylor R., Thielke R., Payne J., Gonzalez N., Conde J.G. Research electronic data capture (REDCap) - a metadata-driven methodology and workflow process for providing tranlsational research informatics support. J Biomed Inform 2009, 42:377-381.
16. Kester L.M., Zimet G.D., Fortenberry J.D., Kahn J.A., Shew M.L. A national study of HPV vaccination of adolescent girls: rates, predictors, and reasons for non-vaccination. Matern Child Health J 2013, 17:879-885.
17. Gowda C., Dong S., Potter R.C., Dombkowski K.J., Dempsey A.F. A population-level assessment of factors associated with uptake of adolescent-targeted vaccines in Michigan. J Adolesc Health 2013, 53:498-505.
18. Baseman J.G., Koutsky L.A. The epidemiology of human papillomavirus infections. J Clin Virol 2005, 32(1):S16-S24.
19. Markowitz L.E., Dunne E.F., Saraiya M., Lawson H.W., Chesson H., et al. Quadrivalent human papillomavirus vaccine: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2007, 56:1-24.
20. Markowitz L.E., Sternberg M., Dunne E.F., McQuillan G., Unger E.R. Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: national health and nutrition examination survey 2003-2004. J Infect Dis 2009, 200:1059-1067.
21. Weiss T.W., Rosenthal S.L., Zimet G.D. Attitudes toward HPV vaccination among women aged 27 to 45. ISRN Obstet Gynecol 2011, 2011:670318.
22. Kahn J.A., Ding L., Huang B., Zimet G.D., Rosenthal S.L., et al. Mothers' intention for their daughters and themselves to receive the human papillomavirus vaccine: a national study of nurses. Pediatrics 2009, 123:1439-1445.
23. Ferris D.G., Waller J.L., Owen A., Smith J. Midadult women's attitudes about receiving the prophylactic human papillomavirus vaccine. J Low Genit Tract Dis 2007, 11:166-172.
24. Ferris D.G., Waller J.L., Owen A., Smith J. HPV vaccine acceptance among mid-adult women. J Am Board Fam Med 2008, 21:31-37.
25. Liau A., Stupiansky N.W., Rosenthal S.L., Zimet G.D. Health beliefs and vaccine costs regarding human papillomavirus (HPV) vaccination among a U.S. national sample of adult women. Prev Med 2012, 54:277-279.
26. Stupiansky N.W., Rosenthal S.L., Wiehe S.E., Zimet G.D. Human papillomavirus vaccine acceptability among a national sample of adult women in the USA. Sex Health 2010, 7:304-309.
27. Short M.B., Rosenthal S.L., Sturm L., Black L., Loza M., et al. Adult women's attitudes toward the HPV vaccine. J Womens Health (Larchmt) 2010, 19:1305-1311.
28. Gargano L.M., Herbert N.L., Painter J.E., Sales J.M., Morfaw C., Rask K., et al. Impact of a physician recommendation and parental immunization attitudes on receipt or intention to receive adolescent vaccines. Hum Vaccin Immunother 2013, 9.
29. Rosenthal S.L., Weiss T.W., Zimet G.D., Ma L., Good M.B., et al. Predictors of HPV vaccine uptake among women aged 19-26: importance of a physician's recommendation. Vaccine 2011, 29:890-895.
30. Rayburn W.F., Petterson S.M., Bazemore A. Preferences of sites for office-based care by reproductive-aged women. Obstet Gynecol 2014, 123(1):88S.
31. Dempsey A., Cohn L., Dalton V.A., Ruffin M. Patient and clinic factors associated with adolescent human papillomavirus vaccine utilization within a university-based health system. Vaccine 2010, 28:989-995.
32. Dempsey A., Cohn L., Dalton V., Ruffin M. Worsening disparities in HPV vaccine utilization among 19-26 year old women. Vaccine 2011, 29:528-534.
33. ACOG ACOG committee opinion no. 558: integrating immunizations into practice. Obstet Gynecol 2013, 121:897-903.
34. Rositch A.F., Nowak R.G., Gravitt P.E. Increased age and race-specific incidence of cervical cancer after correction for hysterectomy prevalence in the United States from 2000 to 2009. Cancer 2014, 120(13):2032-2038.